Skip to Main Content

A year ago, when Merck’s (MRK) latest treatment for Alzheimer’s disease came up a dud, the company saw a silver lining. By targeting patients with early forms of the disease, yet to show major symptoms, researchers saw a winning pathway for the drug, which looked like it was hitting its molecular targets.

They were wrong.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!